Zacks Research Predicts Increased Earnings for Cosmos Health

Cosmos Health Inc. (NASDAQ:COSM) – Zacks Research increased their Q1 2026 earnings per share estimates for shares of Cosmos Health in a report issued on Thursday, April 16th. Zacks Research analyst B. Sorensen now forecasts that the company will post earnings of ($0.01) per share for the quarter, up from their previous forecast of ($0.07). The consensus estimate for Cosmos Health’s current full-year earnings is ($0.11) per share. Zacks Research also issued estimates for Cosmos Health’s Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.06 EPS and FY2026 earnings at $0.08 EPS.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cosmos Health in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Cosmos Health Stock Performance

Shares of COSM stock opened at $0.38 on Tuesday. The stock has a market capitalization of $14.36 million, a PE ratio of -0.63 and a beta of 5.33. Cosmos Health has a 52-week low of $0.28 and a 52-week high of $1.32. The stock’s 50-day moving average price is $0.36 and its 200 day moving average price is $0.55. The company has a quick ratio of 0.85, a current ratio of 1.00 and a debt-to-equity ratio of 0.32.

Insiders Place Their Bets

In other news, CEO Grigorios Siokas purchased 388,532 shares of the firm’s stock in a transaction dated Thursday, February 12th. The shares were acquired at an average price of $0.37 per share, with a total value of $143,756.84. Following the purchase, the chief executive officer directly owned 8,861,914 shares of the company’s stock, valued at $3,278,908.18. The trade was a 4.59% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Over the last 90 days, insiders purchased 770,119 shares of company stock valued at $308,337. 25.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Cosmos Health

Several institutional investors have recently modified their holdings of COSM. XTX Topco Ltd boosted its stake in shares of Cosmos Health by 52.1% during the 4th quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock worth $50,000 after acquiring an additional 34,117 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Cosmos Health by 260.5% during the 4th quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock worth $167,000 after acquiring an additional 241,775 shares in the last quarter. Finally, Citadel Advisors LLC boosted its stake in shares of Cosmos Health by 133.1% during the 3rd quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after acquiring an additional 128,776 shares in the last quarter. Hedge funds and other institutional investors own 12.61% of the company’s stock.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.